ARTHUR KUAN
CHAIRMAN/CEO
CG ONCOLOGY
WHY: The 33-year-old leads research for bladder cancer treatments that investors have called “game changers.”
IN THE NEWS: Went public in January after raising $380M in an IPO, marking the first big public offering in the U.S. this year and the largest IPO for an OC-based firm in over two years.
NOTABLE: Shares of the Irvine-based company soared 96% on its first day as a publicly traded company. Market cap now tops $2B.
QUOTABLE: “We are trying to save people’s lives. We’re looking forward to growing the company.”
